Cargando…
RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated the func...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777567/ https://www.ncbi.nlm.nih.gov/pubmed/35201455 http://dx.doi.org/10.1007/s12672-021-00453-2 |
_version_ | 1784637096825192448 |
---|---|
author | Sasa, Keita Saito, Tsuyoshi Kurihara, Taisei Hasegawa, Nobuhiko Sano, Kei Kubota, Daisuke Akaike, Keisuke Okubo, Taketo Hayashi, Takuo Takagi, Tatsuya Yao, Takashi Ishijima, Muneaki Suehara, Yoshiyuki |
author_facet | Sasa, Keita Saito, Tsuyoshi Kurihara, Taisei Hasegawa, Nobuhiko Sano, Kei Kubota, Daisuke Akaike, Keisuke Okubo, Taketo Hayashi, Takuo Takagi, Tatsuya Yao, Takashi Ishijima, Muneaki Suehara, Yoshiyuki |
author_sort | Sasa, Keita |
collection | PubMed |
description | Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated the functions of endoplasmic reticulum (ER) stress activities in OS and elucidated whether ER stress inhibitors could exert antitumor effects. The expression of 84 key genes associated with unfolded protein response (UPR) was assessed in four OS cells (143B, MG63, U2OS and KHOS) by RT2 Profiler PCR Arrays. Based on results, we performed both siRNA and inhibitor assays focusing on IRE1α-XBP1 and PERK pathways. All OS cell lines showed resistance to PERK inhibitors. Furthermore, ATF4 and EIF2A inhibition by siRNA did not affect the survival of OS cell lines. On the other hand, IRE1α-XBP1 inhibition by toyocamycin suppressed OS cell growth (IC50: < 0.075 μM) and cell viability was suppressed in all OS cell lines by silencing XBP1 expression. The expression of XBP1s and XBP1u in OS cell lines and OS surgical samples were confirmed using qPCR. In MG63 and U2OS, toyocamycin decreased the expression level of XBP1s induced by tunicamycin. On the other hand, in 143B and KHOS, stimulation by toyocamycin did not clearly change the expression level of XBP1s induced by tunicamycin. However, morphological apoptotic changes and caspase activation were observed in these two cell lines. Inhibition of the IRE1α-XBP1s pathway is expected to be a promising new target for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-021-00453-2. |
format | Online Article Text |
id | pubmed-8777567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-87775672022-02-03 RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma Sasa, Keita Saito, Tsuyoshi Kurihara, Taisei Hasegawa, Nobuhiko Sano, Kei Kubota, Daisuke Akaike, Keisuke Okubo, Taketo Hayashi, Takuo Takagi, Tatsuya Yao, Takashi Ishijima, Muneaki Suehara, Yoshiyuki Discov Oncol Research Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated the functions of endoplasmic reticulum (ER) stress activities in OS and elucidated whether ER stress inhibitors could exert antitumor effects. The expression of 84 key genes associated with unfolded protein response (UPR) was assessed in four OS cells (143B, MG63, U2OS and KHOS) by RT2 Profiler PCR Arrays. Based on results, we performed both siRNA and inhibitor assays focusing on IRE1α-XBP1 and PERK pathways. All OS cell lines showed resistance to PERK inhibitors. Furthermore, ATF4 and EIF2A inhibition by siRNA did not affect the survival of OS cell lines. On the other hand, IRE1α-XBP1 inhibition by toyocamycin suppressed OS cell growth (IC50: < 0.075 μM) and cell viability was suppressed in all OS cell lines by silencing XBP1 expression. The expression of XBP1s and XBP1u in OS cell lines and OS surgical samples were confirmed using qPCR. In MG63 and U2OS, toyocamycin decreased the expression level of XBP1s induced by tunicamycin. On the other hand, in 143B and KHOS, stimulation by toyocamycin did not clearly change the expression level of XBP1s induced by tunicamycin. However, morphological apoptotic changes and caspase activation were observed in these two cell lines. Inhibition of the IRE1α-XBP1s pathway is expected to be a promising new target for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-021-00453-2. Springer US 2021-11-30 /pmc/articles/PMC8777567/ /pubmed/35201455 http://dx.doi.org/10.1007/s12672-021-00453-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Sasa, Keita Saito, Tsuyoshi Kurihara, Taisei Hasegawa, Nobuhiko Sano, Kei Kubota, Daisuke Akaike, Keisuke Okubo, Taketo Hayashi, Takuo Takagi, Tatsuya Yao, Takashi Ishijima, Muneaki Suehara, Yoshiyuki RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma |
title | RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma |
title_full | RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma |
title_fullStr | RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma |
title_full_unstemmed | RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma |
title_short | RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma |
title_sort | retracted article: ire1α-xbp1 but not perk inhibition exerts anti-tumor activity in osteosarcoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777567/ https://www.ncbi.nlm.nih.gov/pubmed/35201455 http://dx.doi.org/10.1007/s12672-021-00453-2 |
work_keys_str_mv | AT sasakeita retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT saitotsuyoshi retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT kuriharataisei retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT hasegawanobuhiko retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT sanokei retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT kubotadaisuke retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT akaikekeisuke retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT okubotaketo retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT hayashitakuo retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT takagitatsuya retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT yaotakashi retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT ishijimamuneaki retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma AT sueharayoshiyuki retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma |